Radial artery intima-media thickness regresses after secondary prevention interventions in patients’ post-acute coronary syndrome and is associated with cardiac and kidney biomarkers

Damilola D. Adingupu, Helena U. Westergren, Santosh Dahgam, Ann-Cathrine Jönsson-Rylander, Juuso Blomster, Per Albertsson, Elmir Omerovic, Sara Svedlund and Li-Ming Gan

1 AstraZeneca R&D Gothenburg, Mölndal, Sweden
2 Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden
3 Department of Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden
4 Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden

Correspondence to: Li-Ming Gan, email: li-ming.gan@gu.se

Keywords: atherosclerosis, cardiovascular, intima-media thickness, inflammation, ultrasound

Received: December 28, 2016 Accepted: May 17, 2017 Published: June 16, 2017

Copyright: Adingupu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Background: Radial artery intima-media thickness (rIMT) measured by ultra-high-resolution ultrasound is associated with increased cardiovascular risk and predicts outcomes. We performed non-invasive high-resolution ultrasound of the radial artery to investigate vascular changes in subjects presenting with acute coronary syndrome (ACS) and who had undergone percutaneous coronary intervention (PCI).

Purpose: In the present work, we aimed to follow rIMT change over time post-acute coronary syndrome as a tool to monitor potential response to intensified medical therapy.

Methods: We examined 256 subjects who underwent PCI due to ACS and healthy controls (n=39) and we measured a number of biomarkers, which are known to be associated with cardiovascular disease. Images of radial artery were acquired bilaterally in the longitudinal view using a 50 MHz transducer (Vevo 2100 VisualSonics, Inc, Toronto, Ontario, Canada). Carotid IMT (cIMT) and rIMT were measured at <1 month after index PCI followed by a repeated measurement of rIMT at 4 months from the ACS in a sub-set (n=117).

Results: rIMT measured within 1 month post ACS was significantly higher than rIMT after 4 months from ACS, (p < 0.0001), mean ± SD (rIMT right 0.35 ± 0.08; rIMT left 0.37 ± 0.08) vs. (rIMT right 0.29 ± 0.08; rIMT left 0.31 ± 0.09) respectively. There was no statistically significant change in cIMT. In healthy controls there were no changes in rIMT or cIMT overtime. High levels of CX3CL1 and myeloperoxidase measured within one month post ACS are associated with increase of rIMT, r=0.38 (p< 0.0001) and r=0.41 (p< 0.0001) respectively.

Conclusions: rIMT seem to decrease systemically after ACS and is accompanied with corresponding biomarker change. The cause and clinical implications of the observed decrement in rIMT after ACS need further studies.
INTRODUCTION

Atherosclerosis is a systemic disease which alters the arteries of different vascular beds and is characterized by inflammation [1] and thickening of the intimal and medial layers of the arterial wall [2]. There are various imaging techniques used in the investigation of atherosclerosis in the arterial wall with an emphasis in coronary imaging to assess coronary artery disease as the most significant manifestation of atherosclerotic diseases. Revascularization of coronary artery stenosis leads to both improved quality of life and prolonged survival [3]. Percutaneous coronary intervention (PCI) is however mostly based on morphological assessment of coronary angiography, without direct measure of potential coronary flow limiting properties of these vascular changes. Besides clinical outcome, it is important to be able to assess early the individual response to treatment, which may enable us to identify patients who require further intervention or more intensive medical therapy, thus improving long-term results.

It has been shown that atherosclerosis perturbs the radial arteries [4, 5], which carry similar characteristics to coronary arteries. On the other hand carotid intima media thickness (cIMT) is a well validated and accepted marker of atherosclerosis [6, 7], however it has poor resolution [8] in comparison to radial artery intima-media thickness (rIMT). Furthermore, the sensitivity of cIMT to predict total carotid plaque area has been questioned [9]. We have shown previously that non-invasively measured rIMT using ultra-high-resolution ultrasound is a surrogate marker for atherosclerosis, is associated to cIMT and correlates with various cardiovascular risk factors [10]. Furthermore, rIMT is associated with age, increased cardiovascular risk and predicts outcomes [10, 11] in patients with suspected coronary artery disease. Radial intima thickening has been shown to be present early in the development of hypertension, which is an important risk factor for cardiovascular disease [12]. The radial artery can be studied with relatively less discomfort to patients compared with cIMT, and used on participants as young as 10 years of age [13].

There is a need for imaging technique that is able to detect vascular changes in relatively small patient cohorts, not time-consuming, highly reproducible and can provide specific result in a relatively short time-scale, and thereby can be used in future intervention trials as a response-to-treatment marker. With this respect we investigated temporal changes in rIMT and inflammation biomarkers directly after acute coronary syndrome (ACS) and with repeated measurements in stabilized phase, 4 months after ACS. Kidney impairment and chronic inflammation are known to add incremental risk in individuals with heart failure and ischemic diseases [14, 15], therefore we examined the relation between rIMT, creatinine, cystatin C and inflammatory biomarkers E-selectin, CX3CL1 and MPO.

RESULTS

Patient characteristics

A total of 256 subjects with mean age 65 ± 9 years, 17% women and 83% men were included in the study, and 117 subjects underwent repeated rIMT at 4 months post ACS during the time period of 4 years. The median time to visit 1 from the day PCI was performed was 13 days, and the median time to visit 2 was 19 weeks. Demographic data and medication use are shown in Table 1. Briefly, there were no significant differences in age, clinical characteristics, medication use nor clinical investigations between the whole study cohort and the sub-set having complete measurement of rIMT at visit 1 (<1 month post ACS), Table 1. There was a significant difference in age between healthy controls, whole study cohort and the sub-set cohort (p= 0.0282), which was attributable to healthy controls been younger (Table 1). Biochemical and lipid profile data are presented in Table 2. There were no detectable differences in the sub-set analysis. Lipid profile was improved at visit 2 in ACS subjects, and unchanged in healthy controls.

Changes in IMT with time

There was no statistically significant difference in left or right rIMT measured in healthy controls at visit 1 compared with visit 2 (Table 3). In the sub-set analysis, ACS subjects (n=117) had a significantly higher average rIMT (average of left and right rIMT) compared to healthy controls at visit 1 (0.36±0.07 vs. 0.30±0.04, p<0.0001). There was no statistically significant difference in average rIMT at visit 2 for healthy controls compared with ACS subjects (0.29±0.05 vs. 0.30±0.07). There were no detectable differences between Common carotid IMT measured at visit 1 and 2 (0.07±0.02 and 0.07±0.01 respectively). Healthy controls had a significantly lower average cIMT at visit 1 and 2 compared with ACS subjects (0.07±0.02 vs. 0.80±0.21, p < 0.0001 and 0.07±0.01 vs. 0.81±0.25, p < 0.0001 respectively).

In the subset analysis of 117 ACS subjects, radial IMT at visit 1 was significantly higher than rIMT at visit 2 (4 months post ACS), (p < 0.0001) (Figure 1). There were no detectable differences between Common carotid IMT measured at <1 month post ACS and at 4 months (0.80±0.21 vs. 0.81±0.25).

Relationship between rIMT and CVD risk biomarkers

In the whole cohort (n= 256) who had rIMT investigated at visit 1, we first examined the relation between rIMT, clinical characteristics and blood biomarkers (NT-proBNP, and GDF-15) known to
Table 1: Clinical characteristics and medication use of subjects within 1 month of presenting with ACS and healthy controls at baseline visit

| Parameter                      | Cohort (n = 256) | Sub-set (n = 117) | Healthy controls (n=39) |
|-------------------------------|------------------|-------------------|------------------------|
| Age (years)                   | 64.5 ± 8.6       | 64.5 ± 8.9        | 60 ± 3.5               |
| Men (%)                       | 82.3             | 85.3              | 76.9                   |
| BMI (kg/m2)                   | 25.8 ± 6.8       | 25.8 ± 4.7        | 24.8 ± 2.7             |
| Smokers (% Never, Ex, Current) | 42.7, 35.9, 21.4 (n=206) | 41.1, 38.3, 20.6 (n= 107) | 66.7, 28.2, 5.1       |
| Snuffing (% Never, Ex, Current) | 88.4, 6.3, 5.3 (n=189) | 87.9, 8.1, 4.0 (n= 99) | -                      |
| Diabetes (% Yes)              | 9.7 (n=217)      | 7.1 (n= 114)      | -                      |
| Hypertension (% Yes)          | 45.2 (n= 217)    | 48.2 (n= 114)     | -                      |
| Hyperlipidemic (% Yes)        | 28.6 (213)       | 28.6 (n= 112)     | -                      |
| Previous CABG (% Yes)         | 3.8 (n=216)      | 2.6 (n= 114)      | -                      |
| Previous PCI (% Yes)          | 13.0 (n= 216)    | 13.8 (n= 114)     | -                      |

**Medication use at the time of ACS**

| Medication                  | Cohort (n = 256) | Sub-set (n = 117) | Healthy controls (n=39) |
|-----------------------------|------------------|-------------------|------------------------|
| Aspirin (% Yes)             | 22.9 (n= 214)    | 25.0 (n= 113)     | -                      |
| Beta-blockers (% Yes)       | 21.7 (n= 212)    | 22.4 (n= 111)     | -                      |
| ACE inhibitors (% Yes)      | 11.7 (n= 213)    | 12.9 (n= 112)     | -                      |
| Angiotensin II blocker (% Yes) | 12.7 (n= 213)    | 11.2 (n= 112)     | -                      |
| Statins (% Yes)             | 21.1 (n= 213)    | 21.6 (n= 113)     | -                      |

Data are expressed as mean ± SD for continuous variables and as percentages for categorical variables. ACS: acute coronary syndrome; BMI: body mass index; CABG: coronary artery bypass grafting; PCI: percutaneous coronary intervention. Healthy controls had no previous history of cardiovascular disease and were on no medication at the time of enrolment into the study.

Table 2: Hemodynamic and lipid profile measures taken within 1 month of ACS and at baseline for healthy controls (visit 1) and at visit 2

|                      | Total cholesterol (mg/dl) | LDL-cholesterol (mg/dl) | HDL-cholesterol (mg/dl) | Triglycerides (mg/dl) | Systolic BP (mm Hg) | Diastolic BP (mm Hg) |
|----------------------|---------------------------|-------------------------|-------------------------|-----------------------|---------------------|---------------------|
| Visit 1              |                           |                         |                         |                       |                     |                     |
| Cohort (n = 256)     | 3.85 ± 0.92               | 2.26 ± 0.76             | 1.17 ± 0.31             | 1.19 ± 0.75           | 126 ± 26            | 74 ± 16             |
| Sub-set (n = 117)    | 3.85 ± 0.79               | 2.27 ± 0.67             | 1.15 ± 0.35             | 1.09 ± 0.57           | 125 ± 25            | 74 ± 15             |
| Healthy control (n= 39) | 5.28 ± 0.62             | 3.54 ± 0.55             | 1.51 ± 0.38             | 1.07 ± 0.39           | 131 ± 17            | 81 ± 10             |
| Cohort (n = 249)     | 3.76 ± 0.85***           | 2.09 ± 0.71***          | 1.29 ± 0.33***          | 1.21 ± 0.94           | 132 ± 21*           | 77 ± 12*            |
| Visit 2              |                           |                         |                         |                       |                     |                     |
| Sub-set (n = 113)    | 3.86 ± 0.88**            | 2.17 ± 0.71**           | 1.30 ± 0.32***          | 1.16 ± 0.86           | 130 ± 20            | 75 ± 13             |
| Healthy control (n= 37) | 5.33 ± 0.64             | 3.60 ± 0.58             | 1.56 ± 0.36             | 0.96 ± 0.38           | 124 ± 15**          | 80 ± 9              |

Continuous variables are presented as mean ± SD. BP: blood pressure; HDL: high density lipoprotein; LDL: low density lipoprotein. Statistical differences between groups were tested using Anova. Paired t-test was used for within-group comparison of visit 1 vs. 2, where *** p < 0.001; ** p < 0.01; * p < 0.05 (2-tailed).
be associated with cardiovascular disease [16]. Furthermore, we examined the relation between rIMT and kidney biomarkers creatinine and cystatin C and inflammatory biomarkers CX3CL1, E-selectin and MPO. As shown in Table 4, rIMT significantly correlates with age, BMI, and gender. A number of biomarkers; NT-proBNP (cardiac), CX3CL1, MPO, GDF-15 and E-selectin (inflammatory), creatinine and cystatin C (kidney) and HDL-cholesterol significantly correlates with rIMT measured acutely post ACS (Table 4). We further performed a multivariate analysis adjusted for age, gender, BMI, HDL-cholesterol and diagnosis hypertension. After adjustment rIMT was significantly related to creatinine, Cystatin C, E-Selectin, CX3CL1, MPO and cIMT.

**Comparison of cardiac, kidney and inflammation biomarkers in healthy controls and ACS subjects**

We analyzed cardiac biomarkers Troponin T and NT-proBNP at visit 1 and 2 for healthy controls and ACS subjects. Troponin T and NT-proBNP was significantly lower at visit 2 compared with visit 1 in ACS subjects, however there were no significant difference for healthy controls (Table 5). As expected, healthy controls had a significantly lower Troponin T and NT-proBNP compared

| Parameter | Visit 1 | Visit 2 | Median change (IQR) | p-value |
|-----------|---------|---------|---------------------|---------|
| Healthy Control (n = 39) | | | | |
| Intima media thickness Right (mm) | 0.31±0.05 | 0.30±0.05 | -0.008 (-0.04 to 0.01) | ns |
| Intima media thickness Left (mm) | 0.29±0.05 | 0.28±0.05 | -0.004 (-0.06 to 0.02) | ns |
| ACS (sub-set) Subjects (n = 117) | | | | |
| Intima media thickness Right (mm) | 0.35±0.08 | 0.29±0.08 | -0.05 (-0.32 to 0.17) | < 0.0001 |
| Intima media thickness Left (mm) | 0.37±0.08 | 0.31±0.09 | -0.06 (-0.22 to 0.23) | < 0.0001 |

Data are expressed as mean ± SD or as median (IQR). Paired t-test was used for the comparison of visit 1 vs. 2.
There were no significant changes in cystatin C and creatinine at visit 2 compared with visit 1 for both ACS subjects and healthy controls. However, healthy controls had a significantly lower cystatin C and creatinine at visit 1 and 2 compared with ACS subjects (cystatin C \( p< 0.0001 \) and \( p< 0.0001 \), and creatinine \( p=0.0281 \) and \( p=0.0215 \), respectively).

In healthy controls, GDF-15 and MPO were significantly higher at visit 2 compared with visit 1, and in ACS subjects were significantly lower at visit 2 (Table 5). Healthy controls had a lower GDF-15 at visit 1 and visit 2 compared with ACS subjects (\( p< 0.0001 \) and \( p=0.001 \) respectively). At visit 1, there were no significant differences for MPO between both groups, however at visit 2 ACS subjects had a significantly lower MPO compared with healthy controls (4.01±0.03 vs. 4.32±0.04, \( p< 0.0001 \)). There were no significant differences in E-selectin overtime for healthy controls and ACS subjects and there were no significant differences between both groups at either time point. In ACS subjects, CX3CL1 was significantly lower at visit 2 compared with visit 1, however there was no significant difference over time in healthy controls. There were no significant difference between healthy controls and ACS subjects at visit 1, however at visit 2 ACS subject had a significantly lower CX3CL1 compared with healthy controls (\( p< 0.0001 \)) (Table 5).

**Biomarkers that are associated with increased or reduced rIMT**

We further analyzed the relation between rIMT and inflammatory biomarkers known to play a role in atherosclerosis in the 117 repeatedly investigated ACS subjects. In the regression model CX3CL1 and MPO at visit 1 are associated with regressing or progressing.

### Table 4: Univariate and multivariate correlation between conventional risk factors, patient demographics, biomarkers and average of right and left radial IMT measured within 1 month post ACS (visit 1)

| Parameter                  | Univariate R | Univariate R² | Adjusted R² | n  |
|----------------------------|--------------|---------------|-------------|----|
| Age                        | 0.18**       | 0.03**        | -           | 256|
| Gender                     | 0.22**       | 0.05**        | -           | 256|
| BMI                        | 0.27***      | 0.07***       | -           | 209|
| SBP                        | 0.13         | 0.02          | -           | 216|
| DBP                        | 0.04         | 0.00          | -           | 216|
| HDL-cholesterol            | -0.22**      | 0.05**        | -           | 213|
| LDL-cholesterol            | 0.02         | 0.00          | -           | 213|
| Triglycerides              | 0.12         | 0.01          | -           | 213|
| Cholesterol                | -0.03        | 0.00          | -           | 213|
| Creatinine                 | 0.22**       | 0.05**        | 0.19*       | 213|
| Cystatin C                 | 0.21**       | 0.05**        | 0.18*       | 216|
| Troponin T                 | 0.09         | 0.01          | -           | 144|
| NT-proBNP                  | 0.17*        | 0.03*         | -           | 216|
| GDF-15                     | 0.21**       | 0.04**        | -           | 214|
| E-selectin                 | 0.21**       | 0.05**        | 0.18*       | 216|
| CX3CL1                     | -0.21**      | 0.05**        | 0.19*       | 214|
| MPO                        | -0.22**      | 0.04**        | 0.19*       | 214|
| Common Carotid IMT         | 0.28***      | 0.08***       | 0.19*       | 198|

Univariate R: correlation coefficient, Adjusted R²: coefficient of determination after adjustment for age, gender, BMI, HDL and diagnosis of hypertension. *** \( p < 0.001 \); ** \( p < 0.01 \); * \( p < 0.05 \) (2-tailed). BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; HDL: high density lipoprotein; LDL: low density lipoprotein; NT-proBNP: N-terminal pro b-type natriuretic peptide; GDF-15: growth differentiation factor 15; CX3CL1: C-X3-C motif chemokine ligand 1; MPO: myeloperoxidase; IMT: intima media thickness.

with ACS subjects both at visit 1 and 2 (\( p< 0.0001 \) and \( p< 0.0001 \), respectively).
**DISCUSSION**

In this study we have successfully measured rIMT in subjects after ACS and in healthy subjects. We show that rIMT regresses 4 months post ACS in both left and right radial artery, and is unchanged in healthy subjects within 4 months. As anticipated, we show that healthy controls have a lower rIMT and cIMT measured at baseline compared with ACS subjects, since we have previously shown that rIMT tracks with age and disease severity [10, 11, 13]. We also show that higher rIMT measured within 1 month of ACS correlates with elevated cardiovascular biomarkers creatinine, Cystatin C, E-selectin, CX3CL1 and MPO after adjustments for potential confounders. This suggests an interplay with inflammatory markers and progression of atherosclerosis. Furthermore, we show that inflammatory biomarkers CX3CL1 and MPO measured within 1 month of ACS are directly associated with rIMT. In healthy controls, we show rIMT and cIMT comparable to data previously published [13].

The intima-media complex is composed of the tunica intima and the tunica media. Intima changes may reflect hyperplasia or fibro-cellular hypertrophy in the intima [17], and early changes in the atherosclerosis process. Media thickening reflects hypertrophy and is accelerated by the presence of risk factors for atherosclerosis, importantly hypertension [17, 18]. Intima-media thickness is therefore a combination of the above mentioned processes and thus a good composite marker of cardiovascular risk. The endothelial glycocalyx (EG) is between flowing blood and the endothelial cell lining, and is suggested to be important for shielding the vascular wall from direct exposure to blood flow, contributes to vascular permeability barrier in capillaries, and exhibits anti-adhesive properties [19, 20]. In ACS, there is evidence suggestive of EG damage [21], and atherosclerosis per se has been linked to a reduction of the total EG volume, which was improved with short-term statin therapy [22]. Furthermore in ACS, it is know that there could be endothelial swelling which contributes to microvascular complications post PCI [23]. The composite of these above mentioned mechanisms will result in an acutely increased intima media thickness post PCI, therefore could explain our findings of higher rIMT measured acutely post index event.

**Table 5: Cardiac, kidney and inflammation biomarkers measured at visit 1 and repeated at visit 2 in sub-set ACS subjects and healthy controls**

|                      | Healthy control | Healthy control | ACS (sub-set) subjects | ACS (sub-set) subjects |
|----------------------|-----------------|-----------------|------------------------|------------------------|
|                      | Visit 1         | Visit 2         | Visit 1                | Visit 2                |
| Troponin T           | 4.64 ± 0.45     | 4.65 ± 0.43     | 29.6 ± 2.95            | 10.50 ± 0.76***        |
|                      | (n= 38)         | (n= 37)         | (n= 63)                | (n= 105)               |
| NT-proBNP            | 304 ± 33.23     | 315 ± 45        | 3941 ± 451             | 2353 ± 324***          |
|                      | (n= 38)         | (n= 37)         | (n= 115)               | (n= 110)               |
| Cystatin C           | 1356 ± 33       | 1375 ± 38       | 1618 ± 38              | 1597 ± 35              |
|                      | (n= 38)         | (n= 37)         | (n= 115)               | (n= 110)               |
| Creatinine           | 82.29 ± 1.85    | 81.59 ± 1.87    | 89.27 ± 1.71           | 88.72 ± 1.64           |
|                      | (n= 38)         | (n= 37)         | (n= 113)               | (n= 113)               |
| GDF-15               | 7.78 ± 0.04     | 7.92 ± 0.04     | 8.44 ± 0.06            | 8.28 ± 0.05***         |
|                      | (n= 39)         | (n= 37)         | (n= 113)               | (n= 110)               |
| E-selectin           | 13.64 ± 0.80    | 13.87 ± 0.76    | 13.93 ± 0.57           | 14.49 ± 0.62           |
|                      | (n= 38)         | (n= 37)         | (n= 115)               | (n= 110)               |
| CX3CL1               | 5.02 ± 0.28     | 5.11 ± 0.32     | 4.89 ± 0.54            | 4.56 ± 0.50***         |
|                      | (n= 39)         | (n= 37)         | (n= 113)               | (n= 110)               |
| MPO                  | 4.17±0.04       | 4.32±0.04       | 4.24±0.04              | 4.01±0.03***           |
|                      | (n=39)          | (n=37)          | (n=113)                | (n=110)                |

Data are expressed as mean ± SEM. Paired t-test for parametric or Wilcoxon signed rank test for non-parametric test was used for the within-group comparison of visit 1 vs. 2 where *** p < 0.001; ** p < 0.01; * p < 0.05 (2-tailed).
Figure 2: Linear regression graphs showing changes in radial IMT (increased or decreased rIMT over 4 months) is associated with CX3CL1 (A) and MPO (B) measured at less than 1 month post index event.
Given that coronary artery disease continues to be a major health care burden [24], despite established therapies, sensitive tools are needed in clinical trials of newly developed therapies that will aid the selection of most promising therapies. In this study, we have established a relationship between rIMT and biomarkers (creatine, cystatin C and MPO) which have been suggested to be indicative of poor prognosis in populations with acute coronary syndrome [25–27]. The relationship between increasing burden of atherosclerosis measured by intravascular ultrasound and adverse clinical outcomes have been shown [28]. Our results showing correlation between rIMT and cIMT supports the notion that atherosclerosis is a systemic disease and non-invasively determined rIMT is a potential tool reflecting this systemic nature, thus could be a surrogate marker for coronary artery atherosclerosis [11]. Unsurprisingly, we see correlations between rIMT and age, BMI and gender, which are known to contribute to atherosclerosis and these relationships with rIMT has previously been shown [10]. We see an inverse correlation between HDL-cholesterol and rIMT, but not with LDL-cholesterol. A plausible explanation could be that there could be confounding effects from recommended intensive statin treatment in this patient population, which will mainly have an effect by lowering LDL-cholesterol levels. Furthermore, high HDL-cholesterol is associated with low cardiovascular risk and is suggested to be protective against the development of atherosclerotic disease [29–31], hence the reverse association of HDL with rIMT is conceivable. The reverse association for CX3CL1 and MPO observed within 1 month post ACS remains highly speculative without good understanding currently. Although the lipid profile for healthy controls were higher than for ACS subjects, these values were comparable to published data for the age group studied [32].

We show that rIMT regresses at 4 months post ACS in a relatively small patient cohort. Although we do not have data on the use of statins at 4 months post ACS in this study, we hypothesize that the decreased rIMT 4 months after ACS may be a result of beneficial effect on the vasculature of secondary prevention medication (e.g. statins). In patients with atherosclerotic cardiovascular disease, the standard of care is the use of high-intensity statin therapy [33–35]. The standard of care post ACS in Sweden is also that all patients post PCI receive statin and 75mg aspirin. This is following the current European guidelines which recommends dual antiplatelet therapy of acetylsalicylic acid (Aspirin) plus a P2Y12 inhibitor (i.e., ticagrelor, prasugrel, ticlopidine or clopidogrel) to reduce the risk of thrombus formation in ACS patients [33, 35–37]. Furthermore, at the time of ACS, there is a heightened systemic inflammatory status [56], and in our study this is indicated by the associations of inflammatory markers (E-selectin, CX3CL1 and MPO) with rIMT after adjustments for clinical risk factors. Increased inflammation will trigger a vascular swelling response, which is likely reflected in the higher rIMT measured within 1 month post ACS. It is therefore expected that with the passage of time, intervention and treatment, this vascular swelling should improve. We also observed correlation between rIMT and creatinine, Cystatin C, which further verifies that rIMT is a surrogate marker for systemic disturbance. Creatinine and Cystatin C are both an index of renal function [38, 39], and Cystatin C has been shown to predict outcomes in patients with acute coronary syndrome [14, 40].

Associations between inflammation and increased cIMT has been shown [41–43]. We demonstrate here that there is a direct relationship between levels of inflammatory biomarkers CX3CL1 and MPO measured within 1 month of PCI and individuals who have increased or reduced radial IMT over time. This is an important association given that the progression of atherosclerosis is determined by the derangement of the equilibrium of immune responses [44]. On the endothelium CX3CL1 production induces leucocyte arrest, and may play a role in macrophage and T-cell recruitment to growing lesion, which furthers the progression of atherosclerotic lesion development and is also suggested to mediate pathological processes in cardiovascular disease [45–47]. MPO has been suggested to be a mediator of endothelial dysfunction and atherosclerosis, and elevated levels are associated with the presence of coronary artery disease, and predicts risk in ACS [48, 49]. Furthermore, it has been suggested that MPO binding to the EG decreases the electrostatic repulsion between the endothelium and leukocyte’s surface, thereby inducing leukocyte recruitment, thus promoting inflammatory conditions [50]. Further research is required to enhance our understanding of how leucocyte driving biology drives radial artery atherosclerosis.

Study strengths and limitations

To our knowledge, this is the first study that showed regression of rIMT measured using ultra-high-resolution ultrasound after the treatment of coronary stenosis. Coronary atheroma measured using invasive intravascular ultrasound has previously been shown to regress following high-intensity statin therapy [51, 52]. We believe that with the considerable improvement of the spatial resolution in the new ultrasound platform, rIMT could be an alternative or a complementary method to follow vascular structural changes over a relatively short time in much smaller patient populations.

A limitation is the lack of available data on the use of statins after PCI, and the low population size. The observed relationship between changes in rIMT and CX3CL1 and MPO are relatively weak possibly due to the explorative nature of these biomarkers and also the small population size. In the current study it is also difficult to dissect potential effect of specific medication on rIMT,
therefore future randomized clinical trial is warranted to address this. Further, we included an apparently healthy control group, mainly to serve as a time control rather than to be compared with the patient population, due to the obvious difference between the two groups, in terms of age, gender distribution, medication etc.

In conclusion, in this study we used lipid profile, established cardiovascular biomarkers and explorative inflammation biomarkers to re-verify mechanistic correlates to rIMT. To further our understanding, we explored associations between rIMT and novel biomarkers CX3CL1 and MPO which are implicated in leucocyte mediated inflammatory responses. Taken together lipid profile, kidney and inflammatory markers CX3CL1 and MPO are associated with rIMT status, which supports our hypothesis that rIMT could serve as a surrogate marker for atherosclerosis. We present data showing that radial IMT is reduced after 4 months post ACS and secondary prevention medication. This suggests that rIMT could be used as a tool to monitor potential response to intensified medical therapy or as a new vascular surrogate marker for atherosclerosis in intervention studies.

MATERIALS AND METHODS

Study population

256 subjects with significant coronary atheroma and underwent PCI including stent due to acute coronary syndrome at the Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden were invited to participate in the study, performed during 2010 to 2014. To correct for potential time-dependent changes in all the parameters assessed, we also recruited 39 elderly healthy controls, who underwent a similar study protocol. To be enrolled as healthy controls, the subjects were screened to be free from previous or current diseases requiring medication, dyslipidemia, hypertension, diabetes, and pathological exercise ECG test. Written informed consent was obtained before entry into the study and participants were examined within 1 month of presenting with ACS (visit 1), or baseline for healthy controls (visit 1). All 256 subjects had rIMT and cIMT measured within a month of undergoing PCI, and of the 256 subjects a sub-set of 117 subjects had rIMT repeated at 4 months after ACS or 4 months after baseline visit for healthy controls (visit 2). Methodology and feasibility of rIMT has previously been shown [10]. Demographic data, including history of diabetes, hypertension, hyperlipidemia, previous coronary artery bypass grafting, previous PCI, smoking status and current cardiovascular medication at the time of ACS were collected from the patient medical records. The study was approved by the local ethics committee at the University of Gothenburg and complies with the declaration of Helsinki.

The exclusion criteria included serious illness other than cardiovascular disease, and inability to give informed consent.

High-resolution ultrasound of the radial artery

Both left and right radial arteries were examined non-invasively in longitudinal view, with near and far walls clearly visible, using a 50 MHz transducer with a resolution down to 30 μm (Vevo 2100 VisualSonics, Inc, Toronto, Ontario, Canada). To standardize rIMT image acquisition, previously published protocol was used [13]. Briefly, the transducer was placed in the antebibrachial anterior region at the second skinfold, 1-2 cm proximal to the Palma manus. Digital cine-loops of three consecutive cardiac cycles in B-mode were stored for offline analysis. IMT is defined as the distance between leading edges of the lumen-intima and media-adventitia interfaces [53]. IMT measurements were standardized and performed in peak systole; defined as the frame in systole where the artery had its largest diameter in a cine loop [10]. All offline measurements were done by a single operator who was blinded to the clinical characteristics of the subjects.

Carotid artery intima media thickness

Left and right carotid arteries were examined in the longitudinal view, with near and far walls visible, using a 8 MHz linear transducer (Siemens, Acuson Sequoia 512, Mountain View, California), conforming with recommendations [53]. Measurements of common cIMT was performed 1 cm proximal to the bifurcation, in peak systole and in two different heart beats. Digital cine-loops of three consecutive cardiac cycles were stored for offline analysis. Mean values of the left and right cIMT were used in statistical analysis.

Laboratory analysis

Overnight fasted blood samples were drawn within 30 minutes of rIMT measurement. All biochemical analyses were performed at the Department of Clinical Chemistry, Sahlgrenska University Hospital, Gothenburg or AstraZeneca R&D, Gothenburg, using standard commercially available kits, according to the manufacturer’s protocols. To evaluate lipid profile, we measured serum triglycerides, cholesterol, high density lipoprotein (HDL), low density lipoprotein (LDL) using standard photometric methods in all subjects. In addition to lipid biomarkers, known kidney biomarker Cystatin C was analyzed for kidney status using standard electro-chemiluminescence method, and creatinine analyzed using spectrophotometry. To investigate cardiovascular status, among known biomarkers; Troponin T and N-terminal of the prohormone brain natriuretic peptide (NT-proBNP), were analyzed using standard electro-chemiluminescence methods. Furthermore, growth differentiation factor-15
Growth differentiation factor-15 (GDF-15), Troponin T and NT-proBNP are well established risk biomarkers in the population studied [54]. Growth differentiation factor-15 (GDF-15), E-selectin, Fractalkine (CX3CL1) and myeloperoxidase (MPO) were analyzed using the using the Olink Bioscience (Uppsala, Sweden) Proseek multiplex CVD III panel (multiplexed proximity extension assay) according to the manufacturer’s instructions [55]. All Proseek data are presented as arbitrary units (AU) in log^2 values. E-selectin, CX3CL1 and MPO are inflammatory biomarkers, and were analyzed to investigate inflammatory status and associations with rIMT.

Statistical analysis

Deviations in sample size for the various statistical analyses were due to differences in the availability of clinical demographic data, as well as missing values in some analyzed biomarkers/parameters. Analyses were performed using SPSS, (version 22.0, Chicago Inc., USA) and TIBCO Spotfire, (version 5, TIBCO Software Inc., Boston USA). A p-value of <0.05 (2-tailed) was considered significant. Values are displayed as mean ± SD for continuous variables and percentages for categorical variables. Out of the 256 subjects, a sub-set (n= 117) were completely investigated at visit 1 and visit 2 in regards to rIMT and cIMT and further analyzed in sub-analyses. The test of skewness was used to assess normal distribution. Non-normally distributed variables are presented with their median and interquartile range. Differences among continuous variables were analyzed using paired t test or Wilcoxon Signed rank test, as appropriate and statistical significance for categorical variables was calculated using the chi-squared test. Logistic regression (categorical data) or partial correlation was used in multivariate analysis adjusted for age, BMI, gender, HDL-cholesterol and diagnosis hypertension, selected based on statistical significance and know clinical relevance for the independent parameters.

Abbreviations

ACS: acute coronary syndrome; BMI: body mass index; cIMT: carotid artery intima-media thickness; CVD: cardiovascular disease; GDF-15: growth differentiation factor-15; HDL: high density lipoprotein; LDL: low density lipoprotein; MPO: myeloperoxidase; NT-proBNP: N-terminal of the prohormone brain natriuretic peptide; PCI: percutaneous coronary intervention; rIMT: radial artery intima-media thickness.

Author contributions

Damilola D. Adingupu participated in the data analysis, interpretation and in the writing of the manuscript. Helena U. Westergren participated in the execution of the studies, data acquisition and in the writing of the manuscript. Santosh Dahgam participated in the data analysis and in the writing of the manuscript. Ann-Cathrine Jönsson-Rylander participated in the data interpretation and in the writing of the manuscript. Juuso Blomster participated in the design of the studies, interpretation and in the writing of the manuscript. Per Albertsson and Elmir Omerovic participated in the design and execution of the studies. Sara Sveldlund participated in the design and execution of the studies and in revising of the manuscript. Li-Ming Gan participated in the design of the studies, interpretation, supervision of the project, funding, in the writing of the manuscript and in the final approval.

ACKNOWLEDGMENTS

We are grateful to technicians at Sahlgrenska University hospital for their excellent assistance throughout the study.

CONFLICTS OF INTEREST

There are no conflicts of interest to declare.

FUNDING

This study was funded by Swedish research grants ALF/LUA.

REFERENCES

1. Wilson PW. Evidence of systemic inflammation and estimation of coronary artery disease risk: a population perspective. Am J Med. 2008; 121:S15-20. doi: 10.1016/j.amjmed.2008.06.012.
2. Lahoz C, Mostaza JM. [Atherosclerosis as a systemic disease]. [Article in Spanish]. Rev Esp Cardiol. 2007; 60:184-95. doi: 10.1016/S1885-5857(07)60131-5.
3. Cassar A, Holmes DR, Rihal CS, Gersh BJ. Chronic coronary artery disease: diagnosis and management. Mayo Clin Proc. 2009; 84:1130-46. doi: 10.4065/mcp.2009.0391.
4. Ruengsakulrach P, Sinclair R, Komeda M, Raman J, Gordon I, Buxton B. Comparative histopathology of radial artery versus internal thoracic artery and risk factors for development of intimal hyperplasia and atherosclerosis. Circulation. 1999; 100:II139-44.
5. Moon KW, Kim JH, Yoo KD, Oh SS, Kim DB, Kim CM. Evaluation of radial artery atherosclerosis by intravascular ultrasound. Angiology. 2013; 64:73-9. doi: 10.1177/0003319712437030.
6. Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, Najjar SS, Rembold CM, Post WS. Use
of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr. 2008; 21:93-111. doi: 10.1016/j.echo.2007.11.011.

7. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007; 115:459-67. doi: 10.1161/CIRCULATIONAHA.106.628875.

8. Naqvi TZ, Lee MS. Carotid intima-media thickness and plaque in cardiovascular risk assessment. JACC Cardiovasc Imaging. 2014; 7:1025-38. doi: 10.1016/j.jcmg.2013.11.014.

9. Adams A, Bojara W. [Prediction of coronary artery stenosis by measurement of total plaque area and thickness versus intima media thickness of the carotid artery]. [Article in German]. Herz. 2015; 40:817-22. doi: 10.1007/s00059-015-4312-5.

10. Eklund C, Friberg P, Gan LM. High-resolution radial artery intima-media thickness and cardiovascular risk factors in patients with suspected coronary artery disease--comparison with common carotid artery intima-media thickness. Atherosclerosis. 2012; 221:118-23. doi: 10.1016/j.atherosclerosis.2011.12.035.

11. Eklund C, Omerovic E, Haraldsson I, Friberg P, Gan LM. Radial artery intima-media thickness predicts major cardiovascular events in patients with suspected coronary artery disease. Eur Heart J Cardiovasc Imaging. 2014; 15:769-75. doi: 10.1093/ehjci/jet285.

12. Myredal A, Gan LM, Osika W, Friberg P, Johansson M. Increased intima thickness of the radial artery in individuals with prehypertension and hypertension. Atherosclerosis. 2010; 209:147-51. doi: 10.1016/j.atherosclerosis.2009.09.017.

13. Osika W, Dangardt F, Gronjos J, Lundstam U, Myredal A, Johansson M, Volkmann R, Gustavsson T, Gan LM, Friberg P. Increasing peripheral artery intima thickness from childhood to seniority. Arterioscler Thromb Vasc Biol. 2007; 27:671-6. doi: 10.1161/01.ATV.0000256468.95403.6f.

14. Windhausen F, Hirsch A, Fischer J, van der Zee PM, Sanders GT, van Straalen JP, Cornel JH, Tijsjen JG, Verheugt FW, de Winter RJ. Cystatin C for enhancement of risk stratification in non-ST elevation acute coronary syndrome patients with an increased troponin T. Clin Chem. 2009; 55:1118-25. doi: 10.1373/clinchem.2008.119669.

15. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation. 2004; 109-II-2-II-10. doi: 10.1161/01.cir.0000129535.04194.38.

16. Velders MA, Wallentin L, Becker RC, van Boven AJ, Himmelmann A, Husted S, Katus HA, Lindholm D, Morais J, Siegbahn A, Storey RF, Wernroth L, James SK. Biomarkers for risk stratification of patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: insights from the Platelet Inhibition and Patient Outcomes trial. Am Heart J. 2015; 169:879-89.e7. doi: 10.1016/j.ahj.2015.02.019.

17. Touboul PJ, Hennerici MG, Mearns S, Adams H, Amarenco P, Desvarieux M, Ebrahim S, Fatar M, Hernandez Hernandez R, Kownator S, Prati P, Rundek T, Taylor A, et al. Mannheim intima-media thickness consensus. Cerebrovasc Dis. 2004; 18:346-9. doi: 10.1159/000081812.

18. Lemarie CA, Thauaux PL, Lehoux S. Extracellular matrix alterations in hypertensive vascular remodeling. J Mol Cell Cardiol. 2010; 48:433-9. doi: 10.1016/j.yjmcc.2009.09.018.

19. Henry CB, Duling BR. Permeation of the luminal capillary glycocalyx is determined by hyaluronan. Am J Physiol. 1999; 277:H508-14.

20. van den Berg BM, Spaan JA, Rolf TM, Vink H. Atherogenic region and diet diminish glycocalyx dimension and increase intima-to-media ratios at murine carotid artery bifurcation. Am J Physiol Heart Circ Physiol. 2006; 290:H915-20. doi: 10.1152/ajpheart.00051.2005.

21. Miranda CH, de Carvalho Borges M, Schmidt A, Marin-Neto JA, Pazin-Filho A. Evaluation of the endothelial glycocalyx damage in patients with acute coronary syndrome. Atherosclerosis. 2016; 247:184-8. doi: 10.1016/j.atherosclerosis.2016.02.023.

22. Meuwese MC, Mooij HL, Nieuwdorp M, van Lith B, Mark M, Vink H, Kastelein JJ, Stroes ES. Partial recovery of the endothelial glycocalyx upon rosvastatin therapy in patients with heterozygous familial hypercholesterolemia. J Lipid Res. 2009; 50:148-53. doi: 10.1194/jlr.P800025-JLR200.

23. Jaffe R, Charron T, Puley G, Dick A, Strauss BH. Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention. Circulation. 2008; 117:3152-6. doi: 10.1161/circulationaha.107.742312.

24. Ford ES, Roger VL, Dunlay SM, Go AS, Rosamond WD. Challenges of ascertaining national trends in the incidence of coronary heart disease in the United States. J Am Heart Assoc. 2014; 3:e001097. doi: 10.1161/JAHA.114.001097.

25. Savonitto S, Granger CB, Ariddisi D, Gardner L, Cavallini C, Galvani M, Ottani F, White HD, Armstrong PW, Ohman EM, Pieper KS, Califf RM, Topol EJ, et al. The prognostic value of creatine kinase elevations extends across the whole spectrum of acute coronary syndromes. J Am Coll Cardiol. 2002; 39:22-9.

26. Kilic T, Oner G, Ural E, Yumuk Z, Sahin T, Bildirici U, Acar E, Celikyurt U, Kozdag G, Ural D. Comparison of the long-term prognostic value of cystatin C to other indicators of renal function, markers of inflammation and systolic dysfunction among patients with acute coronary syndrome. Atherosclerosis. 2009; 207:552-8. doi: 10.1016/j.atherosclerosis.2009.05.015.
ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011; 32:2999-3054. doi: 10.1093/eurheartj/ehr236.

37. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, Badano LP, Blömström-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012; 33:2569-619. doi: 10.1093/eurheartj/ehs215.

38. Dharmidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis. 2002; 40:221-6. doi: http://dx.doi.org/10.1053/ajkd.2002.34487.

39. Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem. 1992; 38:1933-53.

40. Akerblom A, Wallentin L, Larsson A, Siegbahn A, Becker RC, Budaj A, Himmelmann A, Horrow J, Husted S, Storey RF, Asenblad N, James SK, PLATO Investigators. Cystatin C- and creatinine-based estimates of renal function and their value for risk prediction in patients with acute coronary syndrome: results from the PLATelet Inhibition and Patient Outcomes (PLATO) study. Clin Chem. 2013; 59:1369-75. doi: 10.1373/clinchem.2012.200709.

41. Liuba P, Persson J, Luoma J, Ylä-Herttuala S, Pesonen E. Acute infections in children are accompanied by oxidative modification of LDL and decrease of HDL cholesterol, and are followed by thickening of carotid intima-media. Eur Heart J. 2003; 24:515-21. doi: 10.1016/s0195-668x(02)00750-9.

42. Engstrom G, Melander O, Hedblad B. Carotid intima-media thickness, systemic inflammation, and incidence of heart failure hospitalizations. Arterioscler Thromb Vasc Biol. 2009; 29:1691-5. doi: 10.1161/ATVBAHA.109.193490.

43. Mattsson N, Magnussen CG, Ronnemaa T, Mallat Z, Benessiano J, Jula A, Taittonen L, Kahonen M, Juonala M, Viikari JS, Raitakari OT. Metabolic syndrome and carotid intima-media thickness: results from the Rancho Bernardo Study 1984–1994. Circulation. 1997; 96:37-43. doi: 10.1161/01.cir.96.1.37.

44. Ferrara A, Barrett-Conner E, Shan J. Total, LDL, and HDL cholesterol decrease with age in older men and women. The Rancho Bernardo Study 1984–1994. Circulation. 1997; 96:37-43. doi: 10.1161/01.cir.96.1.37.

45. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63:2889-934. doi: 10.1016/j.jacc.2013.11.002.

46. Zernecke A, Weber C. Chemokines in the vascular inflammatory response of atherosclerosis. Cardiovasc Res. 2010; 86:192-201. doi: 10.1093/cvr/cvp391.

47. Fong AM, Robinson LA, Steeber DA, Tedder TF, Yoshie O, Imai T, Patel DD. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med. 1998; 188:1413-9. doi: 10.1084/jem.188.8.1413.

48. Zernecke A, Weber KS, Erwig LP, Kluth DC, Schroppel B, Rees AJ, Weber C. Combinatorial model of chemokine
involvement in glomerular monocyte recruitment: role of CXC chemokine receptor 2 in infiltration during nephropathic nephritis. J Immunol. 2001; 166:5755-62.

47. Jones BA, Beamer M, Ahmed S. Fractalkine/CX3CL1: a potential new target for inflammatory diseases. Mol Interv. 2010; 10:263-70. doi: 10.1124/mi.10.5.3.

48. Zhang R, Brennan M, Fu X, Aviles RJ, Pearce GL, Penn MS, Topol EJ, Sprecher DL, Hazen SL. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA. 2001; 286:2136-42. doi: 10.1001/jama.286.17.2136.

49. Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Münzel T, Simoons ML, Hamm CW. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation. 2003; 108:1440-5. doi: 10.1161/01.cir.0000090690.67322.51.

50. Nussbaum C, Klinke A, Adam M, Baldus S, Sperandio M. Myeloperoxidase: a leukocyte-derived protagonist of inflammation and cardiovascular disease. Antioxid Redox Signal. 2013; 18:692-713. doi: 10.1089/ars.2012.4783.

51. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006; 295:1556-65. doi: 10.1001/jama.295.13.jpc60002.

52. Puri R, Nissen SE, Shao M, Uno K, Kataoka Y, Kapadia SR, Tuzcu EM, Nicholls SJ. Impact of baseline lipoprotein and C-reactive protein levels on coronary atheroma regression following high-intensity statin therapy. Am J Cardiol. 2014; 114:1465-72. doi: 10.1016/j.amjcard.2014.08.009.

53. Touboul PJ, Hennerici MG, Mearns S, Adams H, Amarenco P, Bornstein N, Csiba L, Desvarieux M, Ebrahim S, Fatm M, Hernandez Hernandez R, Jaff M, Kornator S, et al. Mannheim carotid intima-media thickness consensus (2004-2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis. 2007; 23:75-80. doi: 10.1159/000097034.

54. Wallentin L, Lindholm D, Siegbahn A, Wernroth L, Becker RC, Cannon CP, Cornel JH, Himmelmann A, Giannitsis E, Harrington RA, Held C, Husted S, Katus HA, et al. Biomarkers in relation to the effects of ticagrelor compared with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the prospective randomized platelet inhibition and patient outcomes (PLATO) trial. Circulation. 2013; 29:293-303. doi: 10.1161/circulationaha.113.004420.

55. Assarsson E, Lundberg M, Holmquist G, Bjorkesten J, Thorsen SB, Ekman D, Eriksson A, Rennel Dickens E, Ohlsson S, Edfeldt G, Andersson AC, Lindstedt P, Stenvang J, et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS One. 2014; 9:e95192. doi: 10.1371/journal.pone.0095192.